Activated Charcoal vs PNC-27
A side-by-side research comparison of Activated Charcoal and PNC-27 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Activated Charcoal | PNC-27 |
|---|---|---|
| Full name | Activated Charcoal (Binder) | PNC-27 (p53-Derived Anticancer Peptide) |
| Category | Detox & Antioxidant | Detox & Antioxidant |
| Status | OTC / Medical device | Research compound (preclinical) |
| Mechanism | Adsorbs toxins via van der Waals forces on its massive activated surface area. Binds mycotoxins (aflatoxin, ochratoxin), bacterial endotoxins (LPS), pesticide residues, and various organic compounds, preventing GI absorption. | Contains a p53 domain fused to a membrane-penetrating sequence. It is proposed to bind HDM-2 that is preferentially expressed on cancer cell membranes, forming pores that cause selective necrosis of cancer cells while reportedly sparing normal cells in studies. |
| Molecular weight | 12.01 Da (elemental carbon) | ~3.2 kDa |
| Half-life | Not absorbed - passes through GI tract | Short (peptide) |
| Bioavailability | Not absorbed systemically (GI binder only) | Injection (research) |
| Typical dose | 500-1000 mg | Not established for humans |
| Frequency | 1-2x daily away from meals/supplements | Research only |
| Route | Oral capsule or powder | Injection (research) |
Activated Charcoal reported benefits
- Mycotoxin binding (mold exposure)
- Endotoxin adsorption
- Acute poisoning treatment
- Reduced die-off symptoms
- GI gas/bloating relief
- Hangover support
PNC-27 reported benefits
- Selective cancer-cell targeting (preclinical)
- p53/HDM-2 mechanism of interest
- Reported sparing of normal cells (studies)
Related comparisons
Research and educational reference only. Not medical advice.